消化性潰瘍治療藥的全球市場:2017年～2021年 -GII

来自 : www.giichinese.com.tw/report/i 发布时间：2021-03-25

Exhibit 01: Types of peptic ulcerExhibit 02: Global peptic ulcer drugs market: Pipeline landscape based on sponsorsExhibit 03: Global peptic ulcer drugs market: Pipeline landscapeExhibit 04: Global peptic ulcer drugs market: List of clinical trials and their aim/purposeExhibit 05: Snapshot of global peptic ulcer drugs marketExhibit 06: Global peptic ulcer drugs market 2016-2021 ($ millions)Exhibit 07: Opportunity analysis in global peptic ulcer drugs marketExhibit 08: Five forces analysisExhibit 09: Segmentation of global peptic ulcer drugs market based on drug class 2016Exhibit 10: Global peptic ulcer drugs market share based on drug class 2016Exhibit 11: Global peptic ulcer PPIs drugs market 2016-2021 ($ millions)Exhibit 12: Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions)Exhibit 13: Global peptic ulcer drugs market for others 2016-2021 ($ millions)Exhibit 14: Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021Exhibit 15: Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021Exhibit 16: Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%)Exhibit 17: Market scenario in AmericasExhibit 18: Peptic ulcer drugs market in Americas 2016-2021 ($ millions)Exhibit 19: Market scenario in EMEAExhibit 20: Peptic ulcer drugs market in EMEA 2016-2021 ($ millions)Exhibit 21: Market scenario in APACExhibit 22: Peptic ulcer drugs market in APAC 2016-2021 ($ millions)Exhibit 23: Age-related proportion of patients with duodenal and gastric ulcerExhibit 24: Some of the marketed combination productsExhibit 25: Revenue erosion of Pariet after loss of exclusivityExhibit 26: Competitive structure analysis of global peptic ulcer drugs market 2016Exhibit 27: AstraZeneca: Key highlightsExhibit 28: AstraZeneca: Strength assessmentExhibit 29: AstraZeneca: Strategy assessmentExhibit 30: AstraZeneca: Opportunity assessmentExhibit 31: Daewoong Pharmaceuticals: Key highlightsExhibit 32: Daewoong Pharmaceuticals: Strength assessmentExhibit 33: Daewoong Pharmaceuticals: Strategy assessmentExhibit 34: Daewoong Pharmaceuticals: Opportunity assessmentExhibit 35: Eisai: Key highlightsExhibit 36: Eisai: Strength assessmentExhibit 37: Eisai: Strategy assessmentExhibit 38: Eisai: Opportunity assessmentExhibit 39: Takeda Pharmaceutical: Key highlightsExhibit 40: Takeda Pharmaceutical: Strength assessmentExhibit 41: Takeda Pharmaceutical: Strategy assessmentExhibit 42: Takeda Pharmaceutical: Opportunity assessment